Clinically, this phenomenon was observed in a patient whose lung cancer carried both epidermal growth factor receptor (EGFR) and MET mutations.7 This patient was treated concomitantly with EGFR TKI osimertinib and type I MET TKI savolitinib. This evidence concerns the gene MET and lung carcinoma.